Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2016-04-18 Investor Presentation
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Investor Presentation Classification · 1% confidence The document is a press release dated April 18, 2016, announcing 'Final Data from Mechanistic Livatag® Study' presented at the AACR Annual Meeting. It details scientific findings, comments from the CSO, and provides context on the drug (Livatag®) and the ongoing Phase III ReLive trial. This content structure—announcing scientific/clinical updates outside of standard periodic financial reports (like 10-K or IR)—is characteristic of an Investor Presentation (IP) or a general press release detailing operational/scientific progress. Since it is a detailed announcement of scientific data supporting the ongoing development, 'Investor Presentation' (IP) is the most fitting category, as these often accompany or summarize such data releases for investors, even if presented in a press release format. It is not a formal regulatory filing like 10-K, nor is it a transcript (CT) or a formal earnings release (ER). Given the focus on detailed scientific results and trial updates aimed at investors, IP is selected over the general 'RNS' fallback.
2016-04-18 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Onxeo S.A. dated April 18, 2016, announcing the presentation of complete study results for their drug Livatag® at the AACR annual conference. It details scientific findings, mentions an ongoing Phase III trial ('ReLive'), and provides context on the disease (Hepatocellular Carcinoma). This type of announcement, focusing on scientific data presentation or preliminary results outside of a formal quarterly/annual filing, is best classified as an Investor Presentation (IP) if it were a deck, or more generally, a press release detailing scientific/clinical progress. Since it is an announcement of results presented at a conference, and not a formal financial report (10-K, IR, ER) or a general regulatory filing (RNS), it aligns closely with the nature of information shared in an Investor Presentation (IP) or a scientific update. However, given the options, it is a detailed announcement of clinical/scientific progress, which often accompanies or substitutes for an Investor Presentation, but since it is a press release format announcing study results, it is most accurately categorized as a specific type of corporate communication. Given the focus on scientific data presentation and clinical trial updates, 'Investor Presentation' (IP) is the closest fit for detailed, non-mandated financial/scientific disclosure, although 'RNS' (Regulatory Filings) is a possibility if it were purely regulatory. Since it is a detailed scientific update presented at a conference, IP is chosen over the generic RNS.
2016-04-18 French
Communicated under the obligation to provide permanent information / Other communications
AGM Information Classification · 1% confidence The document explicitly discusses the results of the 'Extraordinary and Ordinary General Meeting' held on April 6, 2016. It states that 'the Extraordinary and Ordinary General Meeting... adopted all of the resolutions recommended by the Board of Directors' and then directs the reader to where the 'voting results' are available. This content directly relates to the outcome of a shareholder vote at a general meeting. Therefore, the most appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document is short and serves as an announcement regarding the meeting's outcome, not the full AGM presentation (AGM-R) or the proxy materials (PSI).
2016-04-06 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
AGM Information Classification · 1% confidence The document text is titled "Assemblée générale ordinaire et extraordinaire d'Onxeo" (Ordinary and Extraordinary General Meeting of Onxeo) and explicitly states that the 'Assemblée Générale Mixte des actionnaires s'est réunie ce jour' (Mixed General Meeting of shareholders met today) and approved the resolutions. It also mentions where the voting results are available. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R). The document length (5227 chars) is substantial enough to be the primary announcement, not just a brief RPA.
2016-04-06 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release dated April 4, 2016, announcing that Onxeo received a positive recommendation from the Data Safety Monitoring Board (DSMB) to continue its Phase III trial ('ReLive') for the drug Livatag®. This announcement details clinical trial progress, safety data review, and provides general company and product information. It is not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), an earnings release (ER), or a management discussion (MDA). It is an announcement regarding ongoing clinical development and operational updates, which fits best under the general category of Investor Relations material or a specific operational update. Since it is a press release detailing operational progress and clinical trial status, and does not fit the specific definitions for M&A (TAR), Capital (CAP), Dividend (DIV), or Director Dealing (DIRS), it is best classified as a general Regulatory Filing (RNS) as it is a public announcement of material information, or potentially an Investor Presentation (IP) if it were structured as slides, but given the format, RNS is the most appropriate fallback for a general corporate announcement not covered elsewhere.
2016-04-04 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Legal Proceedings Report Classification · 1% confidence The document is a press release dated April 4, 2016, announcing that the Data Safety Monitoring Board (DSMB) recommended the continuation of the Phase III 'ReLive' study for the drug Livatag® without modification, based on positive tolerance data. This type of announcement, detailing clinical trial progress, safety monitoring outcomes, and management commentary on drug development, is characteristic of an update provided to investors regarding ongoing operations and pipeline status. It is not a full Annual Report (10-K), a formal Audit Report (AR), a transcript (CT), or a formal dividend/share change notice. Since it provides key operational and clinical updates, it fits best under the general category of Investor Information or a specific operational update. Given the options, it is a communication aimed at investors about a key asset's clinical trial status. While it could potentially be classified as 'Regulatory Filings' (RNS) as a general press release, the content is highly specific to clinical trial progress and management commentary, which often falls under Investor Presentation (IP) or a general corporate update. However, since it is a press release announcing a specific operational milestone (DSMB recommendation) rather than a formal presentation deck (IP) or a mandatory regulatory filing like a 10-K, and it doesn't fit the other specific categories (like ER, DIV, CAP), it is most appropriately classified as a general corporate/investor communication. Given the available codes, and recognizing this is a news announcement about clinical progress, it is closest to an Investor Presentation (IP) in spirit (providing detailed operational/pipeline updates), but since it is a press release format, 'RNS' (Regulatory Filings/General Announcement) is the safest fallback if a more specific operational code isn't available. Reviewing the definitions, 'IP' is for detailed presentations. This is a press release. Therefore, 'RNS' (Regulatory Filings/General Announcement) is the most suitable general category for a non-standard, non-financial results press release.
2016-04-04 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.